We recently published a list of Jim Cramer Discusses These 12 Stocks & Trump DOJ’s Action Against Health Insurance Companies. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks that Jim Cramer Discusses with insights on Trump DOJ’s action against health insurance companies.

In his recent appearance on CNBC’s Squawk on the Street, Jim Cramer commented on a report in the Wall Street Journal suggesting that the Trump administration’s Department of Justice was aiming to take on one of the largest healthcare insurers in America. While the firm’s shares dropped by 11% on the news, Cramer remained skeptical.

He started out by commenting that “the government has historically not been able to take on this group. They haven’t really taken on the middle-man either. Look I mean we have strong corporations in our country.” Cramer believes that instead of suing the firm, a better approach would be legislation.

“You’re gonna need legislation,” he outlined. “I don’t think you’re going to be able to do anything with the Justice Department,” believes Cramer. He added that “when you have these lawsuits it tends not to bring about any sort of practice. Look, I’m not being cynical. I know that there are people that just say how can you not, how can you not think that this is gonna break up everything?”

While President Trump’s bellicose approach with his administration has turned heads, Cramer shared that little will change at the Justice Department. According to him: “I think that this DOJ is like other DOJs, they’re just not powerful enough to take these companies on. They lose.”

As an example, Cramer pointed to the government’s lawsuits against opioid companies. He shared that while the companies “ended up having to pay,” they were able to continue operating as “nobody got shut down, nobody went to jail, nobody, again this is civil.” Subsequently, Cramer wondered whether “there are certain, companies in the healthcare industry that continue to win, and win, and win. And the initial reaction tends to be an overreaction.”

When told about Bill Ackman’s comments about avoiding the healthcare benefits stock stock and that it was a mental short, he commented:

“Well, again, legislation can do something. This idea of, of creating policy through the Justice Department has not worked. The Justice Department has [inaudible] not been able to create changes. But Congress can. And that’s what has to happen. Look, do I agree with Ackman? I think, I favor universal healthcare [laughs] so I’m way off the reservation. But I do think that if Congress gets involved, as it did under, with Obamacare, they had a shot. Right at the end it was, it was destroyed by the Republican Party. But that’s, that’s what happens.”

Cramer added: “The Justice Department doesn’t do it. . . .Look at what happened to Microsoft, every time the Justice Department really gears up, doesn’t work. Doesn’t change things.”

Our Methodology

To make our list of the stocks that Jim Cramer talked about, we listed down all the stocks he mentioned during CNBC’s Squawk on the Street aired on February 21st.

For these stocks, we also mentioned the number of hedge fund investors. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

An elderly couple receiving insulin from a pharmacist, representing healthcare company's successful pharmaceutical products.

Novo Nordisk A/S (NYSE:NVO)

Number of Hedge Fund Holders In Q4 2024: 64

Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical firm that is a key part of the global weight loss drug industry. Consequently, weight loss drugs are a key part of its hypothesis. This dependence was clear in December when Novo Nordisk A/S (NYSE:NVO)’s shares dipped by 20% after the firm’s weight loss drug trial missed investor estimates. In 2025, the stock is flat after having struggled due to worries about tariffs. However, Novo Nordisk A/S (NYSE:NVO)’s stock rose by 5% in February after the FDA announced that weight loss drug supply constraints were over. Here is what Cramer said:

“By the way, Wegovy’s no longer in short supply and people are taking up Lilly. I [inaudible] Wegovy down and I think that’s probably, I’m not sure that’s necessarily the, the right thing with Lilly.”

Overall, NVO ranks 1st on our list of stocks that Jim Cramer Discusses with insights on Trump DOJ’s action against health insurance companies. While we acknowledge the potential of NVO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than NVO but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap

Disclosure: None. This article is originally published at Insider Monkey.